Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a benzodiazepine with anticonvulsant properties. It is a 1,5-benzodiazepine, differing structurally from the more common 1,4-benzodiazepines. Its mechanism of action is not fully understood but is thought to involve potentiation of GABAergic neurotransmission.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label uses may include other types of epilepsy.
## Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5-10 mg every week to a target maintenance dose.
* **Maintenance:** Typical maintenance dose is 10 mg twice daily.
* **Maximum:** Do not exceed 20 mg twice daily (40 mg/day).
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS) (2 to 18 years of age):**
* **Initiation:** 2.5 mg twice daily.
* **Titration:** Increase dose by 2.5-5 mg every week to a target maintenance dose.
* **Maintenance:** Typical maintenance dose is 5 mg twice daily.
* **Maximum:** Do not exceed 10 mg twice daily (20 mg/day).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustment guidelines are established, but consider a lower starting dose and slower titration.
* **Renal Impairment:** Use with caution. No specific dose adjustment guidelines are established.
* **Elderly:** No specific dose adjustment is recommended, but caution is advised due to potential for increased sensitivity to adverse effects.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic insufficiency.
## Adverse Effects
Common adverse effects include somnolence, decreased appetite, constipation, aggression, irritability, and respiratory tract infections. Serious adverse effects include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms, suicidal behavior or ideation, and paradoxical reactions.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and coma.
* **CYP3A4 Substrates/Inhibitors/Inducers:** Clobazam is metabolized by CYP2C19. CYP3A4 inducers may decrease clobazam levels, while inhibitors may increase them.
* **Antiepileptic Drugs (AEDs):** Monitor for changes in efficacy or toxicity, as clobazam can affect levels of other AEDs and vice versa.
## Monitoring
* Monitor for efficacy (seizure frequency, severity).
* Monitor for adverse effects, particularly somnolence, behavioral changes, and signs of severe skin reactions.
* Monitor for signs of withdrawal upon discontinuation.
* When used with other AEDs, monitor AED serum concentrations if clinically indicated.
## Clinical Pearls
* Clobazam should be tapered slowly upon discontinuation to avoid withdrawal symptoms.
* Due to potential for somnolence, caution patients regarding activities requiring mental alertness, such as driving or operating machinery.
* Consider the risk of serious skin reactions, especially in patients with a history of such reactions.
* Clobazam is a Schedule IV controlled substance.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant literature, and consider individual patient factors before making any treatment decisions.
